Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis

CAMBRIDGE, Mass., July 1, 2019 /PRNewswire/ -- Boston Biomedical, Inc. today announced that the CanStem111P study evaluating the safety and efficacy of investigational agent napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine in patients...

from PR Newswire: https://ift.tt/3254xGI